Biogen has paused or discontinued most of Apellis Pharmaceuticals' research programs and cut some research roles after its $5.6 billion acquisition of Apellis earlier this year. This strategic shift aims to reallocate resources towards Empaveli and Syfovre, the approved therapies gained from the deal. The move follows a review to evaluate the strategic fit of Apellis's portfolio, with Biogen also suspending two trials for Empaveli in kidney-related conditions.

B.Riley has initiated coverage on Nutex Health Inc. (NASDAQ:NUTX) with a Buy rating and a price target of $290.00, suggesting significant upside from the current stock price. The company operates micro-hospitals, addressing a gap in healthcare by combining emergency departments with inpatient services. Nutex Health holds a strong liquidity position and is implementing a new board-approved model to fund and monetize facilities through sale-leasebacks, with plans for 3 to 5 new openings annually.

Automatic Data Processing (ADP) shares traded mutely this week, lagging some NASDAQ-100 service peers despite recent positive hiring data and a Wells Fargo upgrade. The company is positioned as a stable, income-oriented stock due to its consistent cash generation and dividend, contrasting with higher-growth HR and software peers. ADP generates revenue from cloud-based human capital management solutions and is a major provider of payroll and HR services.

Air Products (NYSE: APD) has released its 2026 Sustainability Report, which details the company's economic, environmental, and social performance data from fiscal year 2025. The report is accessible on Air Products' Sustainability website, providing stakeholders with comprehensive information. Air Products, a global industrial gases company, emphasizes its focus on energy, environmental, and emerging markets, including its role as a leading supplier of hydrogen.

Shares of Micron Technology (MU), SanDisk (SNDK), and Western Digital (WDC) fell approximately 7% on Friday, following a significant rally in memory stocks over the past month. This dip is attributed to profit-taking, an Asian chip selloff, and higher-than-expected PCE inflation, rather than a fundamental shift in the AI memory upcycle. Despite Micron's strong Q3 earnings report and optimistic Q4 guidance, the market saw this as an opportunity for traders to lighten their positions in a rapidly appreciating sector.

The Doctors Company has finalized its acquisition of ProAssurance Corporation for approximately $1.3 billion, paying $25.00 per share in cash. ProAssurance will operate as a wholly owned subsidiary of The Doctors Company, and its stock has been delisted from the NYSE. This merger creates a combined entity with $12 billion in assets, serving over 200,000 healthcare professionals.

AbbVie Inc. has reached an all-time high stock price of $245.26, driven by its robust pipeline, strategic acquisitions, and a strong dividend history, though InvestingPro's Fair Value analysis suggests it might be overvalued. The company recently announced the acquisition of Apogee Therapeutics for approximately $10.9 billion, a move that analysts believe will enhance its growth prospects for inflammatory and immunological diseases. AbbVie's board also declared a quarterly cash dividend of $1.73 per share.

MGM Resorts International (NYSE: MGM) will release its Q2 2026 earnings after market close on Wednesday, July 29, 2026. The company will host a conference call at 5:00 p.m. Eastern Time for a discussion of results and a Q&A session, with supplemental slides available on its investor relations website. A replay of the call will be accessible through August 5, 2026.

Truist Securities has increased its price target for PENN Entertainment (NASDAQ:PENN) to $25 from $20, while maintaining a Buy rating. This adjustment follows the successful launch of growth projects, including the new Hollywood Aurora and Hollywood Joliet facilities, which are expected to generate a 15% return on investment and add $54 million in EBITDA. Analysts anticipate PENN to be profitable this year, with InvestingPro suggesting further upside potential to a Fair Value of $27.72.

BMO Capital has reiterated an Outperform rating and an $81.00 price target for CMS Energy (NYSE:CMS), citing a constructive outlook for the company's data center strategy. The firm's analysis, following a meeting with CMS Energy's leadership, signals confidence in the company's near-term and long-term prospects. This comes amidst recent leadership changes and varying analyst opinions on CMS Energy, including a downgrade by Jefferies and an Overweight rating from KeyBanc.